MARKER THERAPEUTICS, INC. Share-based Payment Arrangement, Expense
MARKER THERAPEUTICS, INC. (MRKR) reported Share-based Payment Arrangement, Expense of $195.74 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-14
- MARKER THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $195.74K, a 1299.51% increase year-over-year.
- MARKER THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $178.42K, a 52.94% decline year-over-year.
- MARKER THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $111.54K, a 119.29% increase year-over-year.
- MARKER THERAPEUTICS, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $33.00K, a 37.74% decline year-over-year.
- MARKER THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2025 was $537.54K, a 118.63% increase from fiscal 2024.
- MARKER THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2024 was $245.86K, a 84.47% decline from fiscal 2023.
- MARKER THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2023 was $1.58M, a 70.38% decline from fiscal 2022.
- MARKER THERAPEUTICS, INC. share-based payment arrangement, expense for fiscal 2022 was $5.34M, a 10.40% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $195.74K 10-Q · filed 2026-08-14 | $374.16K 10-Q · filed 2026-08-14 | $485.70K derived: sum of 3 quarters · filed 2026-08-14 | $518.70K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | $178.42K 10-Q · filed 2026-05-15 | $289.96K derived: sum of 2 quarters · filed 2026-05-15 | $322.96K derived: sum of 3 quarters · filed 2026-05-15 | $336.95K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | $111.54K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $144.54K derived: sum of 2 quarters · filed 2026-03-18 | $158.53K derived: sum of 3 quarters · filed 2026-08-14 | $537.54K 10-K · filed 2026-03-18 | |||
| 2025-09-30 | $33.00K 10-Q · filed 2025-11-13 | $46.99K derived: sum of 2 quarters · filed 2026-08-14 | $426.00K 10-Q · filed 2025-11-13 | $476.99K derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | $13.99K 10-Q · filed 2026-08-14 | $14.00K 10-Q · filed 2025-08-14 | $393.13K 10-Q · filed 2026-08-14 | $393.00K 10-Q · filed 2025-08-14 | $443.99K derived: sum of 3 quarters · filed 2026-08-14 | $496.99K derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $379.14K 10-Q · filed 2026-05-15 | $379.00K 10-Q · filed 2025-05-15 | $430.01K derived: sum of 2 quarters · filed 2026-05-15 | $483.01K derived: sum of 3 quarters · filed 2026-05-15 | $546.01K derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $50.86K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $103.86K derived: sum of 2 quarters · filed 2026-03-18 | $166.86K derived: sum of 3 quarters · filed 2026-03-18 | $245.86K 10-K · filed 2026-03-18 | $246.00K 10-K · filed 2025-03-31 | ||
| 2024-09-30 | $53.00K 10-Q · filed 2025-11-13 | $116.00K derived: sum of 2 quarters · filed 2025-11-13 | $195.00K 10-Q · filed 2025-11-13 | $338.00K derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $63.00K 10-Q · filed 2025-08-14 | $142.00K 10-Q · filed 2025-08-14 | $285.00K derived: sum of 3 quarters · filed 2025-08-14 | $460.00K derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $79.00K 10-Q · filed 2025-05-15 | $222.00K derived: sum of 2 quarters · filed 2025-05-15 | $397.00K derived: sum of 3 quarters · filed 2025-05-15 | $1.00M derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $143.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $318.00K derived: sum of 2 quarters · filed 2025-03-31 | $924.00K derived: sum of 3 quarters · filed 2025-03-31 | $1.58M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $175.00K 10-Q · filed 2024-11-14 | $781.00K derived: sum of 2 quarters · filed 2024-11-14 | $1.44M 10-Q · filed 2024-11-14 | $2.16M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | $606.00K 10-Q · filed 2024-08-14 | $1.26M 10-Q · filed 2024-08-14 | $1.98M derived: sum of 3 quarters · filed 2024-08-14 | $3.48M derived: sum of 4 quarters · filed 2024-08-14 | |||
| 2023-03-31 | $660.00K 10-Q · filed 2024-05-15 | $1.38M derived: sum of 2 quarters · filed 2024-05-15 | $2.87M derived: sum of 3 quarters · filed 2024-05-15 | $4.38M derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $717.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $2.21M derived: sum of 2 quarters · filed 2024-03-26 | $3.71M derived: sum of 3 quarters · filed 2024-03-26 | $5.34M 10-K · filed 2024-03-26 | |||
| 2022-09-30 | $1.50M 10-Q · filed 2023-11-09 | $1.50M 10-Q · filed 2022-11-10 | $3.00M derived: sum of 2 quarters · filed 2023-11-09 | $4.63M 10-Q · filed 2023-11-09 | $6.10M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $1.50M 10-Q · filed 2023-08-14 | $1.50M 10-Q · filed 2022-08-11 | $3.13M 10-Q · filed 2023-08-14 | $4.60M derived: sum of 3 quarters · filed 2023-08-14 | $6.07M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $1.63M 10-Q · filed 2023-05-15 | $3.10M derived: sum of 2 quarters · filed 2023-05-15 | $4.57M derived: sum of 3 quarters · filed 2023-05-15 | $6.22M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $2.94M derived: sum of 2 quarters · filed 2023-03-22 | $4.59M derived: sum of 3 quarters · filed 2023-03-22 | $5.96M 10-K · filed 2023-03-22 | |||
| 2021-09-30 | $1.47M 10-Q · filed 2022-11-10 | $3.12M derived: sum of 2 quarters · filed 2022-11-10 | $4.50M 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | $1.65M 10-Q · filed 2022-08-11 | $3.03M 10-Q · filed 2022-08-11 | |||||
| 2021-03-31 | $1.38M 10-Q · filed 2022-05-13 | ||||||
| 2020-12-31 | $5.23M 10-K · filed 2022-03-17 | ||||||
| 2016-09-30 | $573.14K 10-Q · filed 2016-11-04 | $1.31M 10-Q · filed 2016-11-04 | |||||
| 2015-09-30 | $13.24K 10-Q · filed 2016-11-04 | $261.81K 10-Q · filed 2016-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |